Navigation Links
Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
Date:8/27/2007

eart failure, altered heart rate and cardiac arrest, and intestinal complications include an enlarged esophagus or colon. The average lifetime risk of Chagas-infected individuals developing these complications is about 30%. Anti-parasitic medications are usually only effective when given during the acute stage. They can be very toxic, and resistance has already been reported. In the chronic stage of Chagas disease, treatment is limited to managing the clinical manifestations. The scale of the problem is highlighted by the fact that chronic heart disease caused by Chagas is now a major reason for heart transplantation surgery in South America.

Notice Regarding Forward-Looking Statements: This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among others, the expectation and/or claim, as applicable, that: (i) Pacific Pharma's technologies may have potential applications against major tropical parasitic diseases; (ii) Pacific Pharma's technologies may have substantial commercial potential and such technologies fit well with the Company's core competencies in computational-based approaches to biomarker identification; (iii) the Company intends to begin screening compounds against malaria and to test compounds from related classes as potential therapies for tuberculosis; (iv) the Company intends to work with a variety of public and private organizations to ensure timely and cost-effective clinical development of drug candidates generated by its technologies; (v) the Company expects to pursue other therapeutic applications of the technology going forward
'/>"/>

SOURCE Upstream Biosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... 2013 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... at ENDO 2013, the Endocrine Society,s 95 th ... (synchronize) both melatonin and cortisol rhythms. This effect ... body clock and address the circadian desynchrony which ... (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal ...
(Date:6/17/2013)... DNAtrix Inc., experts in oncolytic virus development, today announced ... company,s lead product, DNX-2401, at the Replicating Oncolytic Virus ... on June 18, 2013. Dr. ... the field of oncolytic virus therapy, will present results ... OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS DNX-2401 (FORMERLY KNOWN AS ...
(Date:6/17/2013)... 2013 BioMed Realty Trust, Inc. (NYSE: ... declared a second quarter 2013 dividend of $0.235 per share ... dividend of $0.94 per common share. The ... stockholders of record at the close of business on June ... BioMed Realty delivers optimal real estate solutions for biotechnology ...
Breaking Medicine Technology:Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 3
... Pharmaceutical companies are dramatically increasing their investments ... demands of a patient-empowered, data-driven, outcomes-focused future in ... company investment in smart phone apps, educational websites, ... increased 78%, as companies embrace a role that ...
... Inc. (Nasdaq: MLAB ) today announced that ... cash dividend of 12 cents per share of common ... record at the close of business on February 25, ... markets electronic instruments and disposables for industrial, pharmaceutical and ...
Cached Medicine Technology:Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 2Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 3Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 4Pharmaceutical Industry Rapidly Expanding Partnerships With New Entrants in Health Care Space, Ernst & Young Finds 5
(Date:6/18/2013)... New York (PRWEB) June 18, 2013 As ... both state and federal court, a new report has revealed ... than 70,000 U.S. Food & Drug Administration (FDA) adverse event ... to NewsChannel5 in Cleveland, Ohio, over 4.700 Mirena users have ... while more than 1,300 have reportedly experienced uterine perforations due ...
(Date:6/18/2013)... 2013 New York magazine named 145 physicians ... “Best Doctors” list, up from 129 last year and more ... issue also lists 52 additional doctors who serve at hospitals ... growth trajectory. The “Best Doctors” issue, which this year features ... print issue and is available online at http://www.nymag.com/bestdoctors . ...
(Date:6/18/2013)... York, N.Y., June 18, 2013 -- Lauren Sciences, ... novel V-Smart nanovesicle platform technology, announced today that ... in Drug Delivery with its V-Smart Platform, and ... report by MCD Group. , The ... of Start-ups and Emerging Companies ," features companies ...
(Date:6/18/2013)... their scheduled medical appointments and their disease under ... things clearly and knows them as a person, not ... "If people feel their doctor really knows them and ... best interests at heart and may be more likely ... Flickinger, M.D., M.P.H., a fellow in the Division of ...
(Date:6/18/2013)... officially declared June as Lesbian, Gay, Bisexual ... advances in civil rights, sexual minority youth ... than their heterosexual peers, according to the ... Missouri psychology graduate student recently published recommendation ... youth, which could help improve psychological functioning ...
Breaking Medicine News(10 mins):Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 3Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 3Health News:Respect may be the key to stopping patient 'no shows' 2Health News:Sexual minority youth need specialized treatment from therapists 2
... 10 New and innovative,programs to obtain donor organs ... example, transplant experts are studying a,program they call "living ... friend of a kidney-transplant,patient who is not compatible as ... also may be an incompatible match for his or ...
... old dog new tricks: antimalarial prevents cancer in mice ... researchers from St Jude Childrens Research Hospital, Memphis, and ... drug chloroquine effectively prevents cancer in mouse models of ... telangiectasia. As discussed in the accompanying commentary by Chi ...
... legs can come after infection or cancer therapy, researchers note ... adrenomedullin may prove an effective drug target for treating lymphedema, ... cancer or other cancer treatment, U.S. researchers say. , It ... a team from the University of North Carolina at Chapel ...
... impact boys more than girls, national survey finds , , ... do work to help discourage many teens from becoming ... Wednesday by the U.S. Centers for Disease Control and ... presented in schools and church groups -- did appear ...
... specialty brings more efficient, yet equally safe, patient management, ... A new breed of medical specialists, called hospitalists, can ... long a patient needs to stay in the hospital, ... almost 77,000 hospital stays at 45 centers showed that ...
... Sonography Technology(TM) Developer Cited Number One in Image Quality, ... Ergonomics and ... developer of premium ultrasound systems, today announced it has been,ranked Best ... the,KLAS Top20: Year-End Report published this week. Previously, the company,was ranked ...
Cached Medicine News:Health News:UCLA Program Aims to Revolutionize Kidney Transplants 2Health News:JCI table of contents: Dec. 20, 2007 2Health News:JCI table of contents: Dec. 20, 2007 3Health News:JCI table of contents: Dec. 20, 2007 4Health News:JCI table of contents: Dec. 20, 2007 5Health News:JCI table of contents: Dec. 20, 2007 6Health News:JCI table of contents: Dec. 20, 2007 7Health News:JCI table of contents: Dec. 20, 2007 8Health News:Hormone Could Ease Painful Lymphedema 2Health News:Sex Ed Does Delay Teen Sex: CDC 2Health News:Sex Ed Does Delay Teen Sex: CDC 3Health News:Sex Ed Does Delay Teen Sex: CDC 4Health News:'Hospitalist' Physicians Help Shorten Patient Stays 2Health News:'Hospitalist' Physicians Help Shorten Patient Stays 3Health News:ZONARE Ranked Best in KLAS as Hand Carried Ultrasound Vendor in 2007 Top20: Year-End Report 2Health News:ZONARE Ranked Best in KLAS as Hand Carried Ultrasound Vendor in 2007 Top20: Year-End Report 3
... 1.6 Titanium Cranial Fixation Systems incorporate ... specifically requested by surgeons and surgical ... implants may be either shaped on ... warrants, a pre-measured, cut, bent and ...
1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery....
... DBM Matrix PLF is ... material designed specifically for ... trough-like design allows for ... bone. Demineralized bone fibers ...
Demineralized bone matrix dispensed in a syringe. DBM will be free of foreign matter. Demineralized bone matrix particle size 125 to 850 . Glycerol 70-88% by weight. Calcium content less than 8%....
Medicine Products: